Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy
- 1 January 2021
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 68, 75-83
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
This publication has 71 references indexed in Scilit:
- USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapyMolecular Cancer, 2013
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsGenes & Cancer, 2012
- Selective and Cell-Active Inhibitors of the USP1/ UAF1 Deubiquitinase Complex Reverse Cisplatin Resistance in Non-small Cell Lung Cancer CellsChemistry & Biology, 2011
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsBlood, 2011
- Glioblastoma chemotherapy adjunct via potent serotonin receptor‐7 inhibition using currently marketed high‐affinity antipsychotic medicinesBritish Journal of Pharmacology, 2010
- Cancer risk among users of neuroleptic medication: a population-based cohort studyBritish Journal of Cancer, 2006
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Changes in Food Intake and Stomach Contents of Tumor‐Bearing Rats After Treatment With Dopamine AntagonistsNutrition and Cancer, 1989
- The excretion and metabolism of the long-acting neuroleptic drug fluspirilene in the ratLife Sciences, 1969